HOME >> MEDICINE >> NEWS
More protests against abortion pill

Drug-induced abortion is now legal in the US, but there's a snag...

AFTER a ten-year fight, the "abortion pill" RU486 is finally available in the US. But the pill's supporters fear theirs may be a pyrrhic victory, because production of a second pill that has to be taken with RU486 is now under threat.

RU486 (mifepristone) was approved in Britain nine years ago as an alternative to surgical abortions in the first two months of pregnancy. But American anti-abortion campaigners fought bitterly against it. Now that the US Food and Drug Administration has approved mifepristone, attention has turned to misoprostol, a prostaglandin pill originally developed to treat gastric ulcers.

Supporters of RU486 told New Scientist that they fear anti-abortion campaigners will target misoprostol supply because, although it is officially produced to treat stomach ulcers, obstetricians use it to complete the abortion process started by RU486.

The Reverend Flip Benham, national director of Operation Rescue-one of the most powerful anti-abortion groups in the US-says any drug firms involved in pharmaceutical abortion will be targeted by his group. "If you're going to go ahead and make this pill, you better know that Christians in America do not want to buy pharmaceuticals from you."

RU486 blocks the action of the hormone progesterone, causing the lining of the uterus to break down. Taken two days later, misoprostol makes the uterus contract and the cervix dilate, helping to expel the embryo. But now it seems even the company that makes misoprostol is getting the jitters.

For years, obstetricians have used misoprostol to dilate the cervix during labour. But only when the FDA was about to approve its use with the abortion pill-following pressure from RU486 supporters-did the manufacturer, Pharmacia, send out a sternly worded letter warning against misoprostol's use during pregnancy. The drugs company insis
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-207-331-2751
New Scientist
24-Oct-2000


Page: 1 2

Related medicine news :

1. Strategy effective against drug resistant tuberculosis
2. New study in Nature demonstrates protection against cell death during heart attack
3. Vaccine against childhood pneumonia shows promise
4. Mayo Clinic discovers new pathway against pancreatic cancer
5. Orthodontists must brace against back pain
6. NYUS Duster cautions against FDA approval of race-based pharmaceutical
7. Female sex hormones play a vital role in defense against sexually transmitted diseases
8. New European cancer figures for 2004 major efforts needed against the big four killers
9. New highly active agents against sandfly fever
10. New mosquito control strategy proves successful against dengue fever
11. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: More protests against abortion pill

(Date:1/22/2015)... 2015 Liberty University has received accreditation for ... from the Council for Accreditation of Counseling & Related ... Center for Counseling & Family Studies , is under ... university’s new School of Behavioral Sciences. Prior to the formation ...
(Date:1/22/2015)... January 22, 2015 Woodloch Pines, an ... been selected by TripAdvisor as the number one best large ... best in the world for their annual Travelers’ Choice Awards. ... community . The website is home to millions of unbiased ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3
(Date:1/23/2015)... Fla. , Jan. 23, 2015  HyGreen, Inc., a ... agreement and partnership with RCA Medical, a subsidiary of ... . Each year, hundreds of millions ... care-associated infections as organisms are transmitted from patient to ...
(Date:1/23/2015)... Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange ... shareholders detailing why a "YES" vote to increase the number ... As we reflect upon the 2014 fiscal year that ...
(Date:1/23/2015)... Jan. 23, 2015 Gem Pharmaceuticals announced today that ... enrolled into the Company,s Phase 2 clinical trial.  This ... Gem,s lead compound, GPX-150 (an investigational medication), in approximately ... disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
Cached News: